2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claims
2021
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study
Butala NM, Faridi KF, Tamez H, Strom JB, Song Y, Shen C, Secemsky EA, Mauri L, Kereiakes DJ, Curtis JP, Gibson CM, Yeh RW. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation 2021, 145: 97-106. PMID: 34743530, PMCID: PMC8748407, DOI: 10.1161/circulationaha.121.056878.Peer-Reviewed Original ResearchConceptsContemporary clinical practiceStent-treated patientsPercutaneous coronary interventionDAPT studyProlonged DAPTClinical practiceCoronary interventionMyocardial infarctionNational Cardiovascular Data Registry CathPCI RegistryTreatment effectsTrial resultsAttenuation of benefitLonger-duration DAPTMonths of DAPTProlonged DAPT durationDrug-eluting stentsCoronary stent proceduresModern clinical practiceGreater bleedingMore comorbiditiesRegistry patientsAntiplatelet therapyCerebrovascular eventsDAPT durationMore contemporary cohortsNew Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims)
Faridi KF, Bhalla N, Atreja N, Venditto J, Khan ND, Wilson T, Fonseca E, Shen C, Yeh RW, Secemsky EA. New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims). The American Journal Of Cardiology 2021, 151: 70-77. PMID: 34053629, DOI: 10.1016/j.amjcard.2021.04.019.Peer-Reviewed Original ResearchConceptsIncident heart failureChronic kidney diseaseAcute myocardial infarctionAdvanced chronic kidney diseaseConcurrent heart failureRecurrent myocardial infarctionHeart failureMyocardial infarctionRisk scoreNational Cardiovascular Data Registry CathPCIChest Pain-MI RegistryHistory of HFNew-onset heart failureTime of MINew heart failureSimplified risk scoreOnset heart failureIndex myocardial infarctionFuture heart failureAfrican American raceSpecific risk factorsCumulative incidenceIndependent predictorsKidney diseaseRisk factorsComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2020
Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement
Butala NM, Strom JB, Faridi KF, Kazi DS, Zhao Y, Brennan JM, Popma JJ, Shen C, Yeh RW. Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC Cardiovascular Interventions 2020, 13: 1777-1785. PMID: 32682677, PMCID: PMC7444647, DOI: 10.1016/j.jcin.2020.03.049.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic Valve StenosisBioprosthesisClinical Trials as TopicData AccuracyData MiningDatabases, FactualFemaleHealth Services ResearchHeart Valve ProsthesisHumansInternational Classification of DiseasesMaleMedicarePostoperative ComplicationsReproducibility of ResultsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementAortic valve replacementNegative predictive valuePositive predictive valueValve replacementPivotal trialsAdministrative claimsPredictive valueAortic valve reinterventionProcedural billing codesAcute kidney injuryPermanent pacemaker implantationKappa agreement statisticsBleeding eventsValve reinterventionKidney injuryTrial patientsPacemaker implantationProcedural complicationsOutcome ascertainmentTrial endpointsClinical endpointsMyocardial infarctionInpatient claimsClinical trialsPhysician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study
2016
Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology 2016, 1: 147. PMID: 27437885, DOI: 10.1001/jamacardio.2016.0001.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMedication adherenceClinic visitsHospital dischargeMyocardial infarctionIntervention Outcomes Network RegistryPlatelet P2Y12 receptor inhibitorsAngiotensin-converting enzyme inhibitorAcute Coronary TreatmentFirst outpatient followImproved care transitionsP2Y12 receptor inhibitorsPostdischarge Follow-upAngiotensin receptor blockersSecondary prevention therapiesLong-term prognosisLow medication adherencePatient medication adherenceProportion of daysLower household incomeGuidelines hospitalsReceptor blockersAcute MIClinical characteristicsCoronary Treatment
2015
Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry
Martin SS, Faridi KF, Joshi PH, Blaha MJ, Kulkarni KR, Khokhar AA, Maddox TM, Havranek EP, Toth PP, Tang F, Spertus JA, Jones SR. Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. Clinical Cardiology 2015, 38: 660-667. PMID: 26459191, PMCID: PMC4715617, DOI: 10.1002/clc.22470.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersChi-Square DistributionCholesterolFemaleHumansHypercholesterolemiaKaplan-Meier EstimateLinear ModelsLipoproteinsMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsProspective StudiesProtective FactorsRegistriesRisk AssessmentRisk FactorsTime FactorsTriglyceridesUnited StatesUp-RegulationConceptsAcute myocardial infarctionHigh RLP-C levelsRLP-C levelsRemnant lipoprotein cholesterolLipoprotein cholesterolHazard ratioMyocardial infarctionAcute Coronary Events (GRACE) scoreIntermediate-density lipoprotein cholesterolLow-density lipoprotein cholesterolLipoprotein cholesterol subfractionsMortality 2 yearsUnknown protective factorsLead-time biasRegression hazard ratiosTriglyceride-rich lipoproteinsPrior observational studiesTRIUMPH registryCholesterol subfractionsLowest tertileAMI outcomesAMI survivorsHypercholesterolemic patientsMiddle tertileGlobal Registry